Semaglutide
FDA-approved GLP-1 agonist. The most-studied weight management peptide.
For research use only · Not for human consumption
Every source for Semaglutide
Affiliate disclosure: purchases through links below may earn us a commission. Rankings are never sold — methodology · full disclosure
- ✓Third-party tested (Janoshik)
- ✓COAs provided — Per-batch core, quarterly bonus
- ✓Highest verification tier in stock
- ✓4.8★ community rating
The research base
200+ clinical trials. Strongest evidence base for weight research peptides. Works as researched.
How it works
GLP-1 receptor agonist. Decreases appetite, slows gastric emptying, improves insulin sensitivity.
Common research protocols
Standard FDA titration schedule for Wegovy. Each dose held minimum 4 weeks before increase. GI side effects (nausea, constipation) most pronounced in first 2 weeks of each new dose. If missing dose: take within 5 days, otherwise skip to next scheduled week.
As a solo compound
Strong standalone evidence. Most clinical trials test it alone.
What to know
Common: nausea (30%), GI adjustment. Usually resolve over time.
Realistic expectations
2-4 weeks for appetite suppression, 12+ weeks for significant changes